How have QLGN shares performed in 2024?

Qualigen Therapeutics' stock was trading at $0.55 at the start of the year. Since then, QLGN stock has decreased by 42.2% and is now trading at $0.3180. View the best growth stocks for 2024 here .

Are investors shorting Qualigen Therapeutics?

Qualigen Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 79,900 shares, an increase of 588.8% from the March 15th total of 11,600 shares. Based on an average daily trading volume, of 61,300 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.7% of the shares of the stock are short sold. View Qualigen Therapeutics' Short Interest .

When is Qualigen Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our QLGN earnings forecast .

How were Qualigen Therapeutics' earnings last quarter?

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) released its earnings results on Tuesday, August, 15th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by $0.17. The firm had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.60 million.

What other stocks do shareholders of Qualigen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qualigen Therapeutics investors own include iBio (IBIO) , Boeing (BA) , Sorrento Therapeutics (SRNE) , T2 Biosystems (TTOO) , NIO (NIO) , NVIDIA (NVDA) , Riot Platforms (RIOT) , Vaxart (VXRT) , Boxlight (BOXL) and Enphase Energy (ENPH) .

How do I buy shares of Qualigen Therapeutics?

Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:QLGN

Qualigen Therapeutics (QLGN) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free QLGN Stock Alerts

$0.32

+0.01 (+2.02%)

(As of 05:37 PM ET)

Compare

Today's Range: $0.29
▼
$0.33
50-Day Range: $0.30
▼
$0.58
52-Week Range: $0.28
▼
$1.26

Volume: 30,836 shs
Average Volume: 63,308 shs
Market Capitalization: $2.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Qualigen Therapeutics alerts:

Qualigen Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.74% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.47
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.00) to ($0.71) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.14 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Qualigen Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
1.74% of the float of Qualigen Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Qualigen Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Qualigen Therapeutics has recently increased by 588.79%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Qualigen Therapeutics does not currently pay a dividend.
Dividend Growth
Qualigen Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for QLGN.

1.9

News and Social Media Coverage

News Sentiment
Qualigen Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Qualigen Therapeutics this week, compared to 0 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Qualigen Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.80% of the stock of Qualigen Therapeutics is held by insiders.
Percentage Held by Institutions
Only 3.18% of the stock of Qualigen Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Qualigen Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.71) per share.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Qualigen Therapeutics Stock (NASDAQ:QLGN)

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

QLGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

QLGN Stock News Headlines

April 16, 2024 | markets.businessinsider.com

Qualigen Announced An Agreement With Marizyme To Commercialize DuraGraft

April 16, 2024 | finance.yahoo.com

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 12, 2024 | uk.investing.com

Qualigen presents preclinical novel cancer inhibitors at AACR 2024

April 10, 2024 | globenewswire.com

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

April 9, 2024 | globenewswire.com

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

February 22, 2024 | morningstar.com

Qualigen Therapeutics Inc Ordinary Shares QLGN

February 7, 2024 | uk.investing.com

Qualigen Therapeutics Inc (QLGN)

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

November 27, 2023 | finance.yahoo.com

QLGN: Dosing Begins in Phase 1 Trial of QN-302…

November 14, 2023 | finance.yahoo.com

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

November 7, 2023 | finance.yahoo.com

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

October 23, 2023 | finance.yahoo.com

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

September 27, 2023 | finance.yahoo.com

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

September 2, 2023 | ca.finance.yahoo.com

Qualigen Therapeutics Inc (7R9.DU)

August 30, 2023 | finance.yahoo.com

QLGN: Receives U.S. FDA IND Clearance; Phase 1 Trial to Initiate 2H23…

August 17, 2023 | finance.yahoo.com

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

August 15, 2023 | msn.com

Qualigen Therapeutics GAAP EPS of -$0.69, revenue of $1.62M

August 15, 2023 | finance.yahoo.com

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

August 1, 2023 | finance.yahoo.com

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

July 24, 2023 | finance.yahoo.com

Qualigen Therapeutics Divests FastPack® Diagnostics Business

June 14, 2023 | finance.yahoo.com

QLGN: Data for Pan-RAS Platform Presented at ASCO…

June 6, 2023 | technews.tmcnet.com

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

June 5, 2023 | finance.yahoo.com

Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

May 18, 2023 | seekingalpha.com

Qualigen Therapeutics GAAP EPS of -$0.78, revenue of $1.61M

May 16, 2023 | finance.yahoo.com

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023

May 12, 2023 | finance.yahoo.com

QLGN: IND for QN-302 to be Submitted in Mid-2023…

See More Headlines

Receive QLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/15/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:QLGN
CUSIP: N/A
CIK: 1460702
Web: www.qualigeninc.com
Phone: (760) 918-9165
Fax: N/A
Employees: 31
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,420,000.00
Net Margins: N/A
Pretax Margin: -1,235.43%
Return on Equity: -841.99%
Return on Assets: -137.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.28
Quick Ratio: 0.28

Sales & Book Value

Annual Sales: $4.98 million
Price / Sales: 0.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.41) per share
Price / Book: -0.78

Miscellaneous

Outstanding Shares: 6,310,000
Free Float: 5,941,000
Market Cap: $2.01 million
Optionable: Not Optionable
Beta: -0.81

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Michael S. Poirier (Age 68)
President, COO, CEO & Chairman
Comp: $583.18k
Mr. Christopher L. Lotz (Age 58)
VP of Finance, CFO & Corporate Secretary
Comp: $578.55k

Key Competitors

View All Competitors

QLGN Stock Analysis - Frequently Asked Questions

How have QLGN shares performed in 2024?: Qualigen Therapeutics' stock was trading at $0.55 at the start of the year. Since then, QLGN stock has decreased by 42.2% and is now trading at $0.3180.
View the best growth stocks for 2024 here.
Are investors shorting Qualigen Therapeutics?: Qualigen Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 79,900 shares, an increase of 588.8% from the March 15th total of 11,600 shares. Based on an average daily trading volume, of 61,300 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.7% of the shares of the stock are short sold.
View Qualigen Therapeutics' Short Interest.
When is Qualigen Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our QLGN earnings forecast.
How were Qualigen Therapeutics' earnings last quarter?: Qualigen Therapeutics, Inc. (NASDAQ:QLGN) released its earnings results on Tuesday, August, 15th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by $0.17. The firm had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.60 million.

What other stocks do shareholders of Qualigen Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Qualigen Therapeutics investors own include iBio (IBIO), Boeing (BA), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), NIO (NIO), NVIDIA (NVDA), Riot Platforms (RIOT), Vaxart (VXRT), Boxlight (BOXL) and Enphase Energy (ENPH).
How do I buy shares of Qualigen Therapeutics?: Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QLGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Qualigen Therapeutics (QLGN) Stock Price, News & Analysis